CADTH | Evidence Driven
CADTH | Evidence Driven

Radioimmunotherapy Using 131-Iodine-8H9 for the Treatment of Central Nervous System Neoplastic Tumours: Clinical Effectiveness and Guidelines

Details

Files
Project Status:
Completed
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA0967-000

Question


  1. What is the clinical effectiveness of radioimmunotherapy using 131-Iodine-8H9 radiolabeled antibody conjugate for the treatment of central nervous system neoplastic tumours?

  2. What are the evidence-based guidelines associated with the use of 131-Iodine-8H9 radiolabeled antibody conjugate for the treatment of central nervous system neoplastic tumours?


Key Message

No evidence was identified regarding the clinical effectiveness of radioimmunotherapy using 131-Iodine-8H9 radiolabeled antibody conjugate for the treatment of central nervous system neoplastic tumours. No evidence-based guidelines were identified.


Files

Radioimmunotherapy Using 131-Iodine-8H9 for the Treatment of Central Nervous System Neoplastic Tumours: Clinical Effectiveness and Guidelines Rapid Response September 20, 2018 View PDF

Related Content

Last Updated : September 20, 2018